Rocket Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RCKT | LXEO | SLDB | TNYA | RNA | RGNX | |
|---|---|---|---|---|---|---|
| Market cap | 286.51M | 265.14M | 699.11M | 84.31M | 148.48M | 508.96M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.6 | -2.4 | -3.8 | -0.9 | -1.5 | -2.6 |
| Price/book | 0.8 | 1.1 | 2.9 | 1.2 | 0.7 | 5.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −24.40% | −62.07% | +59.80% | −73.91% | −40.88% | −34.28% |
| Today | +3.98% | +3.86% | +3.82% | +2.66% | −0.46% | +1.05% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All RCKT news ›Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy
RP-A601 was generally well-tolerated at a dose of 8.0E13 GC/kg with no dose-limiting toxicities in all three patients with up to 12 months follow-up Improvement or stabilization observed in arrhythmia burden, heart function, and quality of…
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC
TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients with…
Potent therapy candidate for fatal prion diseases
"The spirit of the collaboration since the beginning has been that there was no waiting on formality," Vallabh says. "As soon as we realized our mutual excitement to do this, everything was off to the races." Co-corresponding authors…
Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference
For more information about Rocket, please visit www.rocketpharma.com and follow us on LinkedIn, YouTube, and X. These forward-looking statements include, but are not limited to, statements concerning Rocket’s planned participation in the…
Rocket Pharmaceuticals enters up to $150M loan deal
Ericsson reports third quarter results 2026 Rocket said existing resources and the initial draw are expected to fund planned operations into the third quarter of 2028. Rocket Pharmaceuticals entered a senior secured term-loan facility with…
Redcare Pharmacy NV : Receives a Buy rating from Jefferies
Jefferies is positive on the stock with a Buy rating. The target price continues to be set at EUR 97. Redcare Pharmacy NV : Receives a Buy rating from Jefferies Published on 08/28/2026 at 08:03 am EDT Latest news about Redcare Pharmacy NV…
All Transcripts on Middle East Pharmaceutical Industries Company (4016)
Find all the latest transcripts on Middle East Pharmaceutical Industries Company Transcripts Middle East Pharmaceutical Industries Company All financial news and data tailored to specific country editions
Cranbury biotech Rocket Pharmaceuticals lands credit facility for up to $150M from Hercules Capital
Gaurav Shah, M.D. - Rocket Pharmaceuticals Rocket Pharmaceuticals Inc., a biotechnology company advancing genetic medicines for rare and life-threatening diseases, announced Oct. 7 that it has entered into a credit facility agreement with…
More from 1 other outlet
Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript
Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data October 6, 2026 4:30 PM EDT Meg Dodge - Senior Vice President & Head of External AffairsGaurav…
Wilson Disease Market Gains Momentum as a First-in-Class Therapy Heads Toward FDA Review and Gene Therapy Advances | Thelansis
Wilson Disease Market Gains Momentum as a First-in-Class openPR.com Wilson Disease Market Gains Momentum as a First-in-Class Therapy Heads Toward FDA Review and Gene Therapy Advances | Thelansis Press release from: THELANSIS KNOWLEDGE…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com17
- defenseworld.net5
- stocktitan.net4
- abfjournal.com1
- gurufocus.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 33 articles, not a forecast.